← All comparisons

CJC-1295 vs Sermorelin

Last updated

The key difference

Both are GHRH analogs. Sermorelin is cleared within minutes. CJC-1295 is modified to resist breakdown, and the version with DAC binds albumin in the blood, extending its action to days.

Side by side

What it is
CJC-1295A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
SermorelinA GHRH analog comprising the first 29 amino acids of growth hormone releasing hormone, historically used to assess and stimulate pituitary GH output. A gentler, physiologic GH peptide.
Research status
CJC-1295Research chemical
SermorelinResearch chemical
Category
CJC-1295Growth Hormone Secretagogues
SermorelinGrowth Hormone Secretagogues
Half-life
CJC-1295DAC version: ~6-8 days; without DAC (Mod GRF 1-29): ~30 minutes
SermorelinApproximately 10-20 minutes
Routes
CJC-1295subcutaneous
Sermorelinsubcutaneous
Reported dosing
CJC-1295Research literature references the DAC form around 1-2 mg weekly, while the no-DAC form is studied at ~100 mcg per dose 1-3 times daily timed to GH pulses. Educational ranges only.
SermorelinResearch and historical clinical references cite ~100-500 mcg per dose, typically once daily before bed to align with nocturnal GH release. Educational reference only.
Studied for
CJC-1295
  • Increases endogenous growth hormone and IGF-1 levels
  • Long half-life allows infrequent administration (DAC version)
  • Supports lean body mass and fat metabolism
  • May improve sleep quality and recovery
Sermorelin
  • Stimulates the body's own GH production
  • Preserves natural GH feedback and pulsatility
  • Supports recovery, body composition, and sleep
  • Historically used in pediatric GH-deficiency diagnostics
Side effects
CJC-1295
  • Water retention and tingling/numbness in extremities
  • Injection-site irritation
  • Headache or flushing
  • Transient increases in hunger or fatigue
Sermorelin
  • Injection-site flushing or pain
  • Headache or dizziness
  • Transient flushing of the face
  • Possible water retention
Cited studies
CJC-12954 on its page
Sermorelin3 on its page

How CJC-1295 works

CJC-1295 is a modified GHRH (1-29) analog that binds the GHRH receptor on pituitary somatotrophs, stimulating endogenous growth hormone synthesis and release. The DAC (Drug Affinity Complex) version adds a lysine linker that binds serum albumin, dramatically extending half-life and prolonging GH and IGF-1 elevation. It preserves the natural pulsatile pattern of GH release rather than producing a constant supraphysiologic level.

Full CJC-1295 profile →

How Sermorelin works

Sermorelin is a truncated GHRH (1-29) analog that binds the pituitary GHRH receptor, stimulating the synthesis and pulsatile release of endogenous growth hormone. Because it works upstream on the pituitary rather than supplying exogenous GH, it preserves natural feedback regulation. Its short half-life produces a brief, physiologic GH pulse, and it synergizes with ghrelin mimetics.

Full Sermorelin profile →

Dosing shown is what research and community sources report, not a recommendation. For educational and research purposes only; not medical advice. How we source this

PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.